Reporter Archive

November 15, 2021

Who’s who in the respiratory landscape

A metatranscriptomics method developed by Vanderbilt researchers simultaneously characterizes viruses, microbiome and host response in nasal swabs, opening opportunities to explore molecular interactions directly in clinical samples.

By Leigh MacMillan
Amya Elliott, 9, talks with Bonnie Pilon, RN, prior to receiving her COVID-19 vaccination at Monroe Carell Jr. Children’s Hospital at Vanderbilt. The hospital began mass vaccination for children ages 5-11 on Monday, Nov. 8.
November 11, 2021

Vaccination day at Children’s Hospital

Monroe Carell Jr. Children’s Hospital at Vanderbilt began mass vaccination for children ages 5-11 on Monday, Nov. 8.

By VUMC News and Communications
Ayaka Sugiura and Jeff Rathmell, PhD, are studying a metabolic enzyme involved in T cell function that may offer a new target for anti-inflammatory therapeutics.
November 11, 2021

CRISPR screen identifies new anti-inflammatory drug target

A novel CRISPR screen developed by Vanderbilt researchers identified a promising new target for anti-inflammatory therapeutics.

By Leigh MacMillan
November 11, 2021

The power of white matter

Using a novel analysis of fMRI data, Vanderbilt researchers discovered intriguing patterns of signals in the brain’s white matter, the “conduit” for relaying signals between different brain regions.

By Bill Snyder
From left, Dandan Liu, PhD, Alan Storrow, MD, and Sunil Kripalani, MD, MSc, are testing the real-world implementation of a risk stratification tool to avoid unnecessary hospital admissions of patients diagnosed with acute heart failure in the emergency department.
November 11, 2021

VUMC team puts tool to reduce heart failure admissions to test

Vanderbilt researchers have developed a risk stratification tool to predict outcomes and avoid unnecessary hospital admissions after emergency department visits for acute heart failure.

By Bill Snyder
Insulin in vials
November 11, 2021

New way to bEET insulin resistance

Signaling molecules called EETs could improve insulin resistance, a primary risk factor for Type 2 diabetes and cardiovascular disease, Vanderbilt researchers have discovered.

By Bill Snyder